Total Payments
$691,173
2024 Payments
$160,887
Companies
83
Transactions
1,634
Medicare Patients
4,469
Medicare Billing
$552,439
Payment Breakdown by Category
Other$455,472 (65.9%)
Travel$102,973 (14.9%)
Consulting$85,185 (12.3%)
Food & Beverage$36,203 (5.2%)
Research$11,004 (1.6%)
Education$336.58 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $450,495 | 130 | 65.2% |
| Travel and Lodging | $102,973 | 263 | 14.9% |
| Consulting Fee | $85,185 | 38 | 12.3% |
| Food and Beverage | $36,203 | 1,177 | 5.2% |
| Unspecified | $11,004 | 9 | 1.6% |
| Honoraria | $4,800 | 4 | 0.7% |
| Education | $336.58 | 12 | 0.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $176.97 | 1 | 0.0% |
Payments by Type
General
$680,169
1,625 transactions
Research
$11,004
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $226,960 | 325 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $155,358 | 251 | $0 (2024) |
| Seagen Inc. | $99,996 | 82 | $0 (2023) |
| Genentech USA, Inc. | $62,598 | 164 | $0 (2024) |
| Gilead Sciences, Inc. | $60,461 | 71 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $30,171 | 106 | $0 (2024) |
| Daiichi Sankyo Inc. | $18,846 | 55 | $0 (2024) |
| Eli Lilly and Company | $12,879 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,925 | 36 | $0 (2024) |
| AstraZeneca UK Limited | $1,794 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $160,887 | 224 | AstraZeneca Pharmaceuticals LP ($65,533) |
| 2023 | $168,861 | 234 | AstraZeneca Pharmaceuticals LP ($53,377) |
| 2022 | $118,060 | 242 | PFIZER INC. ($32,419) |
| 2021 | $55,330 | 139 | Seagen Inc. ($32,624) |
| 2020 | $31,516 | 84 | PFIZER INC. ($18,555) |
| 2019 | $92,523 | 308 | PFIZER INC. ($34,170) |
| 2018 | $53,345 | 220 | Genentech USA, Inc. ($21,367) |
| 2017 | $10,651 | 183 | PFIZER INC. ($6,186) |
All Payment Transactions
1,634 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $30.40 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,250.00 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $29.43 | General |
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $37.89 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $23.37 | General |
| Category: Hematology/Oncology | ||||||
| 12/04/2024 | Menarini Silicon Biosystems, Inc. | Cellsearch (Device) | Food and Beverage | Cash or cash equivalent | $15.04 | General |
| Category: Diagnostics | ||||||
| 11/23/2024 | PFIZER INC. | IBRANCE (Drug) | Travel and Lodging | In-kind items and services | $2,033.65 | General |
| Category: ONCOLOGY | ||||||
| 11/23/2024 | PFIZER INC. | IBRANCE (Drug) | Travel and Lodging | In-kind items and services | $511.36 | General |
| Category: ONCOLOGY | ||||||
| 11/23/2024 | PFIZER INC. | IBRANCE (Drug) | Travel and Lodging | In-kind items and services | $250.43 | General |
| Category: ONCOLOGY | ||||||
| 11/23/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $63.41 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 11/18/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 11/13/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $27.76 | General |
| Category: Hematology/Oncology | ||||||
| 11/05/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $34.48 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $30.44 | General |
| Category: Genetically Defined Disease | ||||||
| 10/24/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $27.54 | General |
| Category: Hematology/Oncology | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $37.55 | General |
| Category: Oncology | ||||||
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $670.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 10/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $3.04 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $0.34 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $9,205 | 6 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $1,499 | 2 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+ HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,003 | 8,711 | $1.4M | $170,211 |
| 2022 | 12 | 951 | 8,942 | $1.2M | $148,042 |
| 2021 | 14 | 1,135 | 8,659 | $996,952 | $122,948 |
| 2020 | 18 | 1,380 | 8,595 | $1.0M | $111,237 |
Total Patients
4,469
Total Services
34,907
Medicare Billing
$552,439
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 37 | 6,247 | $599,535 | $79,429 | 13.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 164 | 371 | $314,608 | $37,631 | 12.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 90 | $102,150 | $14,145 | 13.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 11 | 95 | $109,630 | $11,753 | 10.7% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 151 | 396 | $64,152 | $8,074 | 12.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 161 | 468 | $70,200 | $4,844 | 6.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 160 | 467 | $28,020 | $3,554 | 12.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 159 | 367 | $3,670 | $3,083 | 84.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $23,632 | $2,801 | 11.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 34 | $19,924 | $1,989 | 10.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 45 | 122 | $13,664 | $1,429 | 10.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 13 | 13 | $13,000 | $1,015 | 7.8% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 17 | 25 | $3,675 | $464.50 | 12.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 40 | 6,722 | $599,535 | $76,252 | 12.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 155 | 352 | $298,496 | $35,877 | 12.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 39 | 87 | $98,745 | $12,308 | 12.5% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2022 | 152 | 361 | $58,482 | $7,423 | 12.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 160 | 449 | $67,350 | $4,688 | 7.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 162 | 456 | $27,360 | $3,502 | 12.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $28,063 | $3,093 | 11.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 18 | 31 | $18,042 | $1,802 | 10.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 43 | 121 | $13,552 | $1,511 | 11.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 135 | 302 | $3,020 | $895.44 | 29.7% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2022 | 14 | 24 | $3,528 | $451.62 | 12.8% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 14 | 18 | $2,160 | $238.35 | 11.0% |
About Dr. Linnea Chap, M.D
Dr. Linnea Chap, M.D is a Hematology & Oncology healthcare provider based in Beverly Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700839362.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Linnea Chap, M.D has received a total of $691,173 in payments from pharmaceutical and medical device companies, with $160,887 received in 2024. These payments were reported across 1,634 transactions from 83 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($450,495).
As a Medicare-enrolled provider, Chap has provided services to 4,469 Medicare beneficiaries, totaling 34,907 services with total Medicare billing of $552,439. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Beverly Hills, CA
- Active Since 05/17/2006
- Last Updated 03/25/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1700839362
Products in Payments
- IBRANCE (Drug) $167,035
- TUKYSA (Drug) $102,386
- ENHERTU (Biological) $100,897
- Trodelvy (Drug) $58,650
- Kadcyla (Biological) $21,363
- Perjeta (Biological) $19,964
- TALZENNA (Drug) $18,313
- Herceptin (Biological) $17,912
- PIQRAY (Drug) $15,074
- ENHERTU (Drug) $15,024
- KISQALI (Drug) $10,285
- LYNPARZA (Drug) $9,567
- Enhertu (Drug) $2,646
- BTX (Device) $1,947
- TECENTRIQ (Biological) $1,914
- TRODELVY (Drug) $1,750
- MARGENZA (Drug) $1,500
- Yescarta (Drug) $1,383
- NERLYNX (Drug) $1,300
- Truqap (Drug) $1,064
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Beverly Hills
Dr. Noam Drazin, M.d, M.D
Hematology & Oncology — Payments: $1.7M
Hematology & Oncology $1.7M
Dr. Marina Vaysburd, M.d, M.D
Hematology & Oncology — Payments: $133,758
Hematology & Oncology $133,758
Dr. Barry Rosenbloom, M.d, M.D
Hematology & Oncology — Payments: $106,674
Hematology & Oncology $106,674
Dr. Afshin Gabayan, M.d, M.D
Hematology & Oncology — Payments: $54,070
Hematology & Oncology $54,070
Howard Yeh, Md, MD
Hematology & Oncology — Payments: $22,388
Hematology & Oncology $22,388
Aashini Master, D.o, D.O
Hematology & Oncology — Payments: $20,399
Hematology & Oncology $20,399